DAHANCA 28:超分割加速放疗联合同期顺铂和尼莫拉唑治疗HPV/p16阴性局部晚期头颈鳞癌的I/II期可行性研究
中位随访44个月,3年局部区域失败率为21%,总生存率为74%;急性毒性显著,但晚期严重毒性比例可接受。
要点
- 3年局部区域失败率21%,总生存率74%,所有失败均在高剂量CTV内。
- 急性毒性显著:67%严重吞咽困难,61%严重黏膜炎,78%需置入喂食管。
核心结论
- HART-CN在健康状况良好的HPV/p16阴性局部晚期头颈鳞癌患者中可行,急性毒性显著但晚期毒性比例可接受,3年结局令人鼓舞。
主要发现
- 中位年龄60岁,多数为IV期下咽或口咽癌,有重度吸烟史,所有口咽癌均为HPV/p16阴性。
- 中位观察时间44个月,10例诊断局部区域失败,所有失败均在高剂量CTV内。
- 3年实际局部区域失败率为21%,总生存率为74%。
- 急性毒性峰值:67%严重吞咽困难,61%严重黏膜炎,78%置入喂食管;29例无复发且随访至少3年的患者中7例出现晚期严重并发症(严重吞咽困难2例、严重口干1例、颈部严重纤维化3例、放射性骨坏死1例),其中3例仍依赖喂食管。
关键数值与推荐
- 同期每周顺铂40 mg/m2和尼莫拉唑。
- 主要终点为局部区域失败,次要终点为总生存和毒性。
临床怎么用
- 对于健康状况良好的HPV/p16阴性局部晚期头颈鳞癌患者,可考虑HART-CN方案,但需密切管理急性毒性并关注治疗依从性。
局限性
- 本研究为I/II期可行性研究,样本量50例,非随机对照,结论需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A phase I-II study to evaluate the feasibility and efficacy of intensified, primary radiotherapy (RT) for Locally Advanced Head and Neck Squamous Cell Carcinoma (LAHNSCC) employing dose escalation by hyperfractionation, acceleration of treatment time, concomitant chemotherapy and hypoxic modification. METHODS: Patients with HPV/p16- LAHNSCC receiving primary hyperfractionated, accelerated RT, 76 Gy/56 fx, 10 fx/week for 5½ weeks, concomitant weekly cisplatin (40 mg/m2) and nimorazole (HART-CN) were included. Primary endpoint was locoregional failure (LRF). Secondary endpoints were overall survival (OS) and toxicity. RESULTS: 50 patients received HART-CN from 2013 to 2017. Median age was 60 years. Most patients had stage IV hypo- or oropharynx cancer with a heavy smoking history. All oropharyngeal cancers were HPV/p16-negative. Ninety-eight percent of patients completed RT, but compliance to cisplatin and nimorazole was lower. Median observation time was 44 months. LRF was diagnosed in 10 patients. All LRFs were in the high-dose CTV. The 3-year actuarial LRF was 21%, and OS was 74%. The peak incidence of acute toxicity showed that 67% of patients experienced severe dysphagia, 61% severe mucositis, and 78% were equipped with feeding tubes. Late severe morbidity was seen in 7 of 29 recurrence-free patients with at least 3 years of followup, who presented with either severe dysphagia (n = 2), severe xerostomia (n = 1), severe fibrosis of the neck (n = 3) or osteoradionecrosis (n = 1). Three were still tube dependent. CONCLUSION: HART-CN is feasible in patients with HPV/p16- LAHNSCC in good health. Although acute toxicity was pronounced, the proportion of patients with late toxicity was acceptable and outcome at 3 years encouraging.
引用
- Saksø M, Jensen K, Andersen M, et al. DAHANCA 28: A phase I/II feasibility study of hyperfractionated, accelerated radiotherapy with concomitant cisplatin and nimorazole (HART-CN) for patients with locally advanced, HPV/p16-negative squamous cell carcinoma of the oropharynx, hypopharynx, larynx and oral cavity. Radiother Oncol. 2020. PMID: 32335364. doi:10.1016/j.radonc.2020.03.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。